Clinical Trial Detail

NCT ID NCT01831726
Title Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Dovitinib

Age Groups: senior adult

Additional content available in CKB BOOST